Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
4.670
-0.080 (-1.68%)
At close: Jun 23, 2025, 4:00 PM
4.750
+0.080 (1.71%)
After-hours: Jun 23, 2025, 7:39 PM EDT
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
233.98M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
CADL News
- 17 hours ago - Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer - GlobeNewsWire
- 17 days ago - Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - GlobeNewsWire
- 26 days ago - Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer - GlobeNewsWire
- 27 days ago - Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation - GlobeNewsWire
- 4 weeks ago - Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 - GlobeNewsWire
- 5 weeks ago - Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 6 weeks ago - Candel Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 - GlobeNewsWire